What is the medical insurance reimbursement rate for bedaquiline?

Bedaquiline is a new anti-tuberculosis drug used to treat multidrug-resistant tuberculosis (MDR-TB). It was developed by the overseas pharmaceutical company Gilead Sciences (Janssen Pharmaceuticals). It belongs to a class of drugs called ATP synthase inhibitors. It effectively inhibits bacteria by targeting the energy metabolism pathway of Mycobacterium tuberculosis. Bedaquiline has a different mechanism of action than traditional anti-tuberculosis drugs and therefore shows good efficacy in treating drug-resistant tuberculosis.

The clinical application of bedaquiline is mainly targeted at patients who are resistant to existing anti-tuberculosis drugs (such as isoniazid, rifampin). Treatment options for these patients are relatively limited, and the introduction of bedaquiline provides them with new treatment opportunities. Studies have shown that when used in combination with other anti-tuberculosis treatment options, bedaquiline can significantly increase cure rates and reduce treatment time.

In China, bedaquiline was approved for marketing in2019, marking an important progress in the treatment of multi-drug-resistant tuberculosis in China. After it was put on the market, the State Food and Drug Administration conducted relevant safety and effectiveness evaluations to provide patients with a more effective treatment option. Bedaquiline has been gradually included in the national medical insurance directory since its launch.

In the latest medical insurance policy, bedaquiline is applicable to specific multi-drug-resistant tuberculosis patients, and its reimbursement rates may vary in different provinces. Normally, the medical insurance reimbursement ratio ranges from 70% to 90%, which means that patients can enjoy relatively high cost reductions when using bedaquiline, reducing their financial burden. However, due to the relatively high price of bedaquiline, patients still have to bear a certain out-of-pocket cost for actual use despite medical insurance support.